EDCTP Alumni Network

Fostering excellence and collaboration in the next generation of researchers

All Profiles

Associate Professor Selidji Todagbe Agnandji

Call Senior Fellowship (SF)
Programme EDCTP2
Start Date 2020-01-01
End Date 2024-12-31
Project Code TMA2017SF-1946
Status Active

Title

Strengthening vaccine research at CERMEL focusing on biomedical and social sciences

Host Organisation

Institution Country
Centre de Recherches Médicales de Lambaréné (CERMEL) Gabon

Current Organisation

Centre de Recherches Médicales de Lambaréné (CERMEL)

Current Job Title

Research group leader and Director

Students Supervised

Type Name Title University Start Date End Date
Biotechnology Christine Ndong Master ( candidate) Target: University of Tübingen/ Leiden university Medical Center (LUMC) 2022 2024
Social sciences ( Sociology) Pamela Minsoko Angoissa Master (Candidate) University Jean Jaures, Toulouse, France 2022 2024
Biomedicine / Data analysis Juste Bie Master ( Candidate) Ulster University (UK): Online programme 2022 2024
Biomedicine/Vaccinology Armel Vivien Mbouna Ndong PhD ( Candidate) _Amsterdam Medical center 2022 2026
Clinical medicine/Vaccinology Peter Fungai MusangoMunei PhD ( Candidate) Target: Amsterdam Medical center 2022 2026
Biomedicine/Health policy Ayodele Alabi PhD Candidate Leiden University Medical Center 2020 2025

Memberships

Role Committee/board Start Date End Date
Member Scientific Review Committee of CERMEL 2012
Member Institutional Review Board of CERMEL 2012
Director Board of Directors of CERMEL 2013
Editor Frontiers Immunology 2020

Education

Institution Degree Year
University of Health Sciences, Gabon MD 2004-03-01
University of Tübingen, Germany PhD 2012-12-20
University Jean Jaures, France Master social sciences 2012-10-01
University Aix -Provence, France Master Health Sciences 2008-10-01

Grants

Publications

Pyronaridine–artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study
Authors:
Gaston Tona Lutete , author
Elizabeth A. Ashley , editor
Ghyslain Mombo-Ngoma , author
Serge-Brice Assi , author
Jude D. Bigoga , author
Felix Koukouikila-Koussounda , author
Nsengi Y. Ntamabyaliro , author
Francine Ntoumi , author
Selidji T. Agnandji , author
Mirjam Groger , author
Jangsik Shin , author
Isabelle Borghini-Fuhrer , author
Sarah Arbe-Barnes , author
Stephen J. Allen , author
Peter G. Kremsner , author
Robert Miller , author
Stephan Duparc , author
Michael Ramharter , author
Date:
2021-06-15
Journal:
PLOS Medicine
Content:
Safety, immunogenicity and risk–benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I–III clinical trials across regions
Authors:
Bache Emmanuel Bache , author
Martin P Grobusch , author
Selidji Todagbe Agnandji , author
Date:
2020-01-01
Journal:
Future Microbiology
Content:

Projects

A multilateral initiative to foster the clinical development of effective malaria vaccine candidates
Fellow:
Selidji Todagbe Agnandji
Collaborators:
Name Country Institution
Selidji Todagbe AGNANDJI Gabon CERMEL
Objectives:
The overall objective of the MIMVaC-Africa consortium is to accelerate the development of highly effective malaria vaccines that meet the goals set by the WHO Malaria Vaccine Technology Roadmap
Sites:
2.entre de Recherches Médicales de Lambaréné (CERMEL), Gabon 3. Fundação Manhiça, Mozambique 4. Ifakara Health Institute Trust (IHI), United Republic of Tanzania, 5. Academisch Ziekenhuis Leiden (LUMC), Netherlands 6. European Vaccine Initiative EWIV (EVI), Germany 7. The Chancellor, the Masters and the Scholars of the University of Oxford, United Kingdom 8. Eberhard Karls Universität Tübingen (EKUT), Germany 9. Luxembourg Institute of Health (LIH), Luxembourg 10. Osaka University, Japan
Study Design:
Conduct phase 1/2 CHMI trials followed by a phase 2b multicenter trials in the African children under natural exposure to P. falciparum infection in very experienced and GCP compliant research institutions in Africa to generate evidence that will support smooth progress to large phase 3 trials 4. Engage a dialogue with regulatory authorities, Ministries of Health, and important local and international stakeholders about setting a mechanism that would facilitate continuous engagement to report the progress of the project, and discuss requirements for expedited deployment of a successful candidate.
Subjects:
Children aged 1-12 years and adults
Outcomes:
Malaria vaccine candidate eligible for a phase 3 clinical trial in sub-Saharan African populations
Start Date:
2021-10-01
End Date:
2026-09-30
COVID-19 AND FRAGILE PATIENTS Multicenter observational study to assess the incidence and features o
Fellow:
Selidji Todagbe Agnandji
Collaborators:
Name Country Institution
Selidji Todagbe AGNANDJI Gabon CERMEL
Objectives:
To describe the rate, the etiology (SARS-CoV-2 variants), the severity of COVID-19, and the rate of re-infections in several types of fragile patients.
Sites:
Università degli Studi di Verona (UNIVR), Alma Mater Studiorum – Università di Bologna (UNIBO); Institut National de la Sante et de la Recherche Medicale (INSERM); Servicio Andaluz de Salud (SAS); Consorzio Interuniversitario (CINECA); Luxembourg Institute of Health (LIH); Assistance Publique Hopitaux de Paris (APHP); Regione Emilia Romagna (RER-ASSR); Fundacion Privada Instituto de Salud Global Barcelona (ISGLOBAL); Ludwig-Maximilians-Universitaet Muenchen (LMU MUENCHEN); Universiteit Antwerpen (UANTWERPEN); Helmholtz Zentrum Muenchen Deutsches Forschungszentrumfuer Gesundheit und Umwelt GMBH (HMGU); Klinikum der Universitaet zu Koeln (UHC); Fondazione PENTA – for the treatment and care of children with HIV and related diseases - ONLUS (PENTA); Universitaet Stuttgart (USTUTT); Centre de Recherches Medicales DE Lambaréné (CERMEL); Regionalny Urad Verejneho Zdravotnictva so siidlom v Banskejbytrici(RAPH BB); Charité – Universitaetsmedizin Berlin (CHARITÉ); Academisch Ziekenhuis Groningen (UMCG); Centre Informatique National de l’Enseignement Superieur (CINES); Universidad de Oviedo (UNIOVI); Universidad de Buenos Aires (UBA); Institutul National de Sanatate Publica (INSP), Regione del Veneto (REG VEN); Fondation Congolaise pour la Recherche Medicale (FCRM); Translational Health Science and Technology Institute (THSTI), Faridabad, Haryana, India; Catholics Bishops Conference of India, Society for Medical Education (CBCI), Bangalore, India; Escola Paulista de Medicina -Universidade Federal de São Paulo, Brazil.
Study Design:
Multicenter, multinational observational study aimed at building several types of fragile populations in which to assess the rate and the clinical spectrum of COVID-19, with particular interest in long-term follow-up
Subjects:
Children aged 1-12 years
Outcomes:
To assess the incidence of COVID-19 in several types of fragile populations
Start Date:
2021-10-01
End Date:
2023-09-30

Send a Message